pacemakers and especially for arterial or venous stents including balloon expandable stents in certain embodiments inventive compounds may be bound to an implantable medical device or alternatively may be passively adsorbed to the surface of the implantable device in certain other embodiments the inventive compounds may be formulated to be contained within or adapted to release by a surgical or medical device or implant such as for example stents sutures indwelling catheters prosthesis and the like for example drugs having antiproliferative and anti inflammatory activities have been evaluated as stent coatings and have shown promise in preventing retenosis see for example presbitero p et al u201c drug eluting stents do they make the difference u201d minerva cardioangiol 2002 50 5 431 442 ruygrok p n et al u201c rapamycin in cardiovascular medicine u201d intern med j 2003 33 3 103 109 and marx s o et al u201c bench to bedside the development of rapamycin and its application to stent restenosis u201d circulation 2001 104 8 852 855 each of these references is incorporated herein by reference in its entirety accordingly without wishing to be bound to any particular theory applicant proposes that inventive compounds having antiproliferative effects can be used as stent coatings and or in stent drug delivery devices inter alia for the prevention of restenosis or reduction of restenosis rate suitable coatings and the general preparation of coated implantable devices are described in u s pat nos 6 099 562 5 886.